To evaluate whether targeting V-ATPase can be a widely applicable strategy in inducing PrCR, we then assessed the effects of blocking V-ATP activity by pharmacological inhibitors to inhibit its ATPase function in a wider range of human cancer cells including lymphoma, colon cancer and breast cancer (Figures 3A–D). This evidence concerns the gene DNAH8 and breast carcinoma.